Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.67 |
| ▸ | PHGDH | O43175 | 1/20 | 0.64 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 4/20 | 0.58 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | GRM5 | P41594 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3242724 | 0.85 | RAB9A (0.65) | SMN1; SMN2ALDH1A1RAB9AHPGDKDM4E | |
| SCHEMBL423224 | 0.85 | RAB9A (0.65) | SMN1; SMN2ALDH1A1RAB9AHPGDKDM4E | |
| SCHEMBL31392086 | 0.85 | RAB9A (0.65) | SMN1; SMN2ALDH1A1RAB9AHPGDKDM4E | |
| SCHEMBL990908 | 0.84 | GRM5 (0.63) | SMN1; SMN2ALDH1A1RAB9AHPGDKDM4E | |
| SCHEMBL20460596 | 0.84 | GRM5 (0.63) | SMN1; SMN2ALDH1A1RAB9AHPGDKDM4E | |
| SCHEMBL28477730 | 0.83 | RAB9A (0.62) | SMN1; SMN2ALDH1A1RAB9AHPGDGRM5 | |
| SCHEMBL13210615 | 0.83 | SMN1; SMN2 (1.00) | SMN1; SMN2ALDH1A1PHGDHRAB9APKM | |
| SCHEMBL2235373 | 0.83 | SMN1; SMN2 (0.72) | SMN1; SMN2ALDH1A1PHGDHRAB9APKM | |
| SCHEMBL17974448 | 0.82 | SMN1; SMN2 (0.62) | SMN1; SMN2ALDH1A1PHGDHPKMHPGD | |
| SCHEMBL3402254 | 0.81 | SMN1; SMN2 (0.70) | SMN1; SMN2ALDH1A1PHGDHRAB9APKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023229380-A1 | HETEROCYCLIC COMPOUND AS DIACYLGLYCEROL KINASE INHIBITOR AND USE THEREOF | 주식회사 엘지화학 | 2023-11-30 | — | — | WO | disclosed |
| WO-2023229380-A1 | HETEROCYCLIC COMPOUND AS DIACYLGLYCEROL KINASE INHIBITOR AND USE THEREOF | 주식회사 엘지화학 | 2023-11-30 | — | — | WO | disclosed |
| US-20230373985-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | ORIGENIS GMBH (DE) | 2023-11-23 | — | — | US | disclosed |
| US-20230373985-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | ORIGENIS GMBH (DE) | 2023-11-23 | — | — | US | disclosed |
| EP-3181554-B1 | QUINAZOLINE DERIVATIVE | CSPC ZHONGQI PHARMACEUTICAL TECH SHIJIAZHUANG CO LTD (CN) | 2020-10-28 | — | — | EP | disclosed |
| US-10774079-B2 | Quinazoline derivative | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2020-09-15 | — | — | US | disclosed |
| US-10421754-B2 | Quinazoline derivative | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2019-09-24 | — | — | US | disclosed |
| EP-3157920-B1 | INDOLIZINE DERIVATIVES AS PHOSPHOINOSITIDE 3-KINASES INHIBITORS | CHIESI FARM SPA (IT) | 2019-08-07 | — | — | EP | disclosed |
| EP-2300465-B1 | IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES | ASTEX THERAPEUTICS LTD (GB) | 2019-04-17 | — | — | EP | disclosed |
| US-20170226099-A1 | QUINAZOLINE DERIVATIVE | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2017-08-10 | — | — | US | disclosed |
| WO-2004056369-A1 | BENZO ‘ D!AZEPINE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | GLAXO GROUP LIMITED (GB) | 2004-07-08 | — | — | WO | disclosed |
| WO-2004046120-A2 | DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2004-06-03 | — | — | WO | disclosed |
| EP-1370546-A2 | NOVEL AMINES AS HISTAMINE-3 RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | Abbott Laboratories (US) | 2003-12-17 | — | — | EP | disclosed |
| US-6534504-B1 | Increasing the quantity of meat or improving the quality of meat obtained from a livestock animal, comprising administering to the animal an effective amount of a compound represented by the following structural formula: | ELI LILLY AND COMPANY | 2003-03-18 | — | — | US | disclosed |
| US-20020183309-A1 | Novel amines as histamine-3 receptor ligands and their therapeutic applications | ABBOTT LABORATORIES | 2002-12-05 | — | — | US | disclosed |
| US-20020177589-A1 | Novel amines as histamine-3 receptor ligands and their therapeutic applications | ABBOTT LABORATORIES | 2002-11-28 | — | — | US | disclosed |
| US-20020169188-A1 | Novel amines as histamine-3 receptor ligands and their therapeutic applications | ABBVIE INC. | 2002-11-14 | — | — | US | disclosed |
| WO-2002074758-A2 | NOVEL AMINES AS HISTAMINE-3 RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | ABBOTT LABORATORIES (US) | 2002-09-26 | — | — | WO | disclosed |
| WO-2001035947-A2 | TREATING WASTING SYNDROMES WITH ARYLOXY PROPANOLAMINES | ELI LILLY AND COMPANY (US) | 2001-05-25 | — | — | WO | disclosed |
| WO-2001036390-A1 | INDAZOLYLOXY PROPANOLAMINES FOR IMPROVING LIVESTOCK PRODUCTION | ELI LILLY AND COMPANY (US) | 2001-05-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373985-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | TYK2, MAPKAPK2, MAP3K20 | SMN1; SMN2 3815/4885ALDH1A1 4878/4885PHGDH 3356/4885 |
| US-10774079-B2 | Quinazoline derivative | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TOP2A, TOP1 | SMN1; SMN2 4518/4885ALDH1A1 2644/4885PHGDH 1045/4885 |
| US-20020177589-A1 | Novel amines as histamine-3 receptor ligands and their therapeutic applications | HRH3, HRH4, HRH1 | SMN1; SMN2 3319/4885ALDH1A1 664/4885PHGDH 1194/4885 |
| US-10421754-B2 | Quinazoline derivative | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TOP2A, TOP1 | SMN1; SMN2 4518/4885ALDH1A1 2644/4885PHGDH 1045/4885 |
| US-20020169188-A1 | Novel amines as histamine-3 receptor ligands and their therapeutic applications | HRH3, HRH4, HRH1 | SMN1; SMN2 3319/4885ALDH1A1 664/4885PHGDH 1194/4885 |
| US-20170226099-A1 | QUINAZOLINE DERIVATIVE | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TOP2A, TOP1 | SMN1; SMN2 4518/4885ALDH1A1 2644/4885PHGDH 1045/4885 |
| US-20020183309-A1 | Novel amines as histamine-3 receptor ligands and their therapeutic applications | HRH3, HRH4, HRH1 | SMN1; SMN2 3319/4885ALDH1A1 664/4885PHGDH 1194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.